reference/4373216

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4373216

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase III\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, P.H.S.
endingPage	588
issn	0022-3476
issueIdentifier	5
pageRange	581-588
publicationName	The Journal of Pediatrics
startingPage	581
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5a0eb2fadabf1dffb4d70280b760adba
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_46e8db71352ebf3d2d6248da9f10f379
bibliographicCitation	Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004 May;144(5):581–8. doi: 10.1016/j.jpeds.2004.01.046. PMID: 15126990.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16f64120cd3b5615555a249daeed69c6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38da3836c16e142d8d5a05ba15ef5bf0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16b6073444aa400363818e9f63ab3bd3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4855-2600 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa495c5e7fd570564adf4f814b75f341 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc87bde69f4d2da316cb16387bd37e9f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ffdaca542e1c6bcf8c2a9984d2457df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a319ff485ce9751e8945ce79c04cc593 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd386ff02f2873abe6a2b2a1fd8bc5a7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93d94fa63cdfabe6bf6bac78348560eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c68f1cf88826bdae58bb5c230cdd3483 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31ea6d05c98d0ba0523feea4b238979b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f25a6188ed252121fdcca9ac848b719 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f58b56f7fa1cc48b0745188d5d7d257 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b8eec6cd63765009496b5bd796464f6
date	200405
identifier	https://pubmed.ncbi.nlm.nih.gov/15126990 https://doi.org/10.1016/s0022-3476%2804%2900091-5 https://doi.org/10.1016/j.jpeds.2004.01.046
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5127 https://portal.issn.org/resource/ISSN/0022-3476
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human $alpha;-L-iduronidase (laronidase)*1
discusses	http://id.nlm.nih.gov/mesh/M0018641 http://id.nlm.nih.gov/mesh/M0010998
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D007068Q000627 http://id.nlm.nih.gov/mesh/D008059Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D018709 http://id.nlm.nih.gov/mesh/D002648 http://id.nlm.nih.gov/mesh/D000704 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D008059Q000150 http://id.nlm.nih.gov/mesh/D007068Q000009 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D011994 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D012131Q000209 http://id.nlm.nih.gov/mesh/D012131Q000188
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7999 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9249 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d1eea675fce19801eb167f92266218ba http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8332

Total number of triples: 57.